Glucose Homeostasis and Genotype-Phenotype Interplay in Cystic Fibrosis Patients With CFTR Gene ΔF508 Mutation
- Vanessa Preumont, MD1,
- Michel P. Hermans, MD, PHD1,
- Patrick Lebecque, MD, PHD2 and
- Martin Buysschaert, MD, PHD1
- 1Department of Endocrinology and Nutrition, Université Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels, Belgium
- 2Cystic Fibrosis Unit, Université Catholique de Louvain, Cliniques Universitaires St-Luc, Brussels, Belgium
- Address correspondence and reprint requests to Prof. M. Buysschaert, Cliniques Universitaires St-Luc, Service d'Endocrinologie et Nutrition, Avenue Hippocrate 54, UCL 5474, B-1200 Brussels, Belgium. E-mail: buysschaert{at}diab.ucl.ac.be
Abstract
OBJECTIVE—We sought to determine the clinical phenotype of adolescent/adult patients with cystic fibrosis, according to heterozygosity or homozygosity for cystic fibrosis transmembrane regulator (CFTR) ΔF508 mutation, and to analyze their characteristics according to glucose tolerance status.
RESEARCH DESIGN AND METHODS—A total of 76 cystic fibrosis patients with CFTR ΔF508 mutation (33 heterozygous and 43 homozygous) stratified according to normal glucose tolerance (NGT) (n = 51) or abnormal glucose homeostasis (AGH) (impaired fasting glucose, impaired glucose tolerance, or diabetes; n = 25) had their homeostasis model assessment (HOMA) of β-cell function and of insulin sensitivity and hyperbolic product (β-cell function × insulin sensitivity [B × S]) measured. Pancreatic exocrine insufficiency was inferred from pancreatine requirements. Clinical effects of insulin therapy on weight and lung function were recorded.
RESULTS—AGH was observed in 24 and 40% of heterozygous and homozygous subjects, respectively. AGH patients were older than NGT patients (mean ± SD age 29 ± 10 vs. 23 ± 8 years, P = 0.006), and their β-cell function was lower (93 ± 49 vs. 125 ± 51%, P = 0.011). Insulin sensitivity values were comparable in NGT and AGH patients. A lower B × S product was observed in AGH, although it was nonsignificant when adjusted for error propagation. Pancreatic insufficiency was observed in 52 and 100% of heterozygous and homozygous patients (P = 0.001).
CONCLUSIONS—Pre-diabetes and diabetes represent frequent comorbidities in CFTR ΔF508 mutation in the homozygous or heterozygous states. Impairment of insulin secretion, as shown by HOMA, is an important determinant when compared with the magnitude of compensation from insulin sensitivity. Given the high prevalence of abnormal glucose tolerance, screening for (pre-)diabetes is mandatory. Insulin supplementation in diabetic subjects with CFTR ΔF508 mutation seems a rational therapy for consideration, although this does not preclude that therapy directed toward insulin resistance could also interact.
- AGH, abnormal glucose homeostasis
- B × S, β-cell function × insulin sensitivity
- FEV1, forced expiratory volume over 1 s
- FVC, forced vital capacity
- HOMA, homeostasis model assessment
- HOMA-B, HOMA of β-cell function
- HOMA-S, HOMA of insulin sensitivity
- IFG, impaired fasting glucose
- IGT, impaired glucose tolerance
- NGT, normal glucose tolerance
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 2 March 2007. DOI: 10.2337/dc06-1915.
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Accepted February 7, 2007.
- Received September 12, 2006.
- DIABETES CARE











